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Some suggest race-specific cutpoints for kidney measures to
define and stage chronic kidney disease (CKD), but evidence
for race-specific clinical impact is limited. To address this
issue, we compared hazard ratios of estimated glomerular
filtration rates (eGFR) and albuminuria across races using
meta-regression in 1.1 million adults (75% Asians, 21%
Whites, and 4% Blacks) from 45 cohorts. Results came mainly
from 25 general population cohorts comprising 0.9 million
individuals. The associations of lower eGFR and higher
albuminuria with mortality and end-stage renal disease
(ESRD) were largely similar across races. For example, in
Asians, Whites, and Blacks, the adjusted hazard ratios (95%
confidence interval) for eGFR 45–59 versus 90–104ml/min per
1.73m2 were 1.3 (1.2–1.3), 1.1 (1.0–1.2), and 1.3 (1.1–1.7) for
all-cause mortality, 1.6 (1.5–1.7), 1.4 (1.2–1.7), and 1.4 (0.7–2.9)
for cardiovascular mortality, and 27.6 (11.1–68.7), 11.2
(6.0–20.9), and 4.1 (2.2–7.5) for ESRD, respectively. The
corresponding hazard ratios for urine albumin-to-creatinine
ratio 30–299mg/g or dipstick 1þ versus an albumin-to-
creatinine ratio under 10 or dipstick negative were 1.6
(1.4–1.8), 1.7 (1.5–1.9), and 1.8 (1.7–2.1) for all-cause mortality,
1.7 (1.4–2.0), 1.8 (1.5–2.1), and 2.8 (2.2–3.6) for cardiovascular
mortality, and 7.4 (2.0–27.6), 4.0 (2.8–5.9), and 5.6 (3.4–9.2) for
ESRD, respectively. Thus, the relative mortality or ESRD risks
of lower eGFR and higher albuminuria were largely similar
among three major races, supporting similar clinical
approach to CKD definition and staging, across races.
Kidney International (2014) 86, 819–827; doi:10.1038/ki.2013.553;
published online 12 February 2014
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Chronic kidney disease (CKD) is a global public health
problem,1–3 affecting 10–16% of the adult population in
several continents4–7 and increasing the risk of adverse out-
comes.8–12 The definition and staging of CKD is based on the
level of glomerular filtration rate (GFR) and the presence of
kidney damage, usually ascertained as albuminuria.1,11,13
However, the comparability of GFR and albuminuria mea-
sures across racial groups and their relationship with risk
have not been fully explored,14 although some have suggested
race-specific thresholds for GFR and albuminuria to define
and stage CKD.15 The primary objective of this study was
to quantify the associations of GFR and albuminuria with
risk for all-cause and cardiovascular mortality, and end-stage
renal disease (ESRD) among Asians, Whites, and Blacks,
three major races in the world, and assess whether there are
any substantial differences across the races.
RESULTS
Study populations
A total of 1,130,472 individuals were studied, including
75% Asians (mostly Eastern Asians), 21% Whites, and 4%
Blacks. Majority of the study population, 83% or 940,366
http://www.kidney-international.org c l in i ca l inves t iga t ion
& 2014 International Society of Nephrology
Correspondence: Josef Coresh, Chronic Kidney Disease Prognosis Con-
sortium Data Coordinating Center, 615 North Wolfe Street, Baltimore,
Maryland 21205, USA. E-mail: ckdpc@jhmi.edu
Received 31 July 2013; revised 23 October 2013; accepted 21 November
2013; published online 12 February 2014
Kidney International (2014) 86, 819–827 819
individuals, were from 25 general population cohorts, with
the remaining 13% or 151,494 individuals from 7 high-risk
cohorts, and 3% or 38,612 individuals from 13 CKD cohorts
(Table 1). Thus, our primary analyses were conducted in the
general population cohorts, and results for the high-risk
cohorts and CKD cohorts were shown in Supplementary
Materials separately. Asians comprised the majority of the
general population cohorts (87%), but not the high-risk
(6%) or CKD (12%) cohorts, and mainly came from cohorts
based on data from comprehensive health screening pro-
grams for the healthy population. Accordingly, Asians tended
to have a lower risk profile (younger age and lower prevalence
of comorbid conditions) as compared with Whites and
Blacks. Although most Asians were from Asian cohorts, most
Blacks were from US cohorts. There were differences in the
methods for ascertainment of albuminuria among the general
population cohorts: only 1% of Asians had albumin-to-
creatinine ratio (ACR) data, whereas ACR data were available
in 73% of Whites and 100% of Blacks included in the meta-
analysis, reflecting different medical and research settings.
Estimated glomerular filtration rate and albuminuria
distributions by race
In the general population cohorts, the crude prevalence of
reduced estimated glomerular filtration rate (eGFR;o60ml/
min per 1.73m2) in Asians, Whites, and Blacks was 5.1, 15.8,
and 9.4%, respectively (Supplementary Figure S1A online).
The prevalence of elevated albuminuria (X30mg/g by ACR
or X1þ by urine dipstick) in the three races was 2.8, 9.9,
and 16.6%, respectively (Supplementary Figure S1B online).
The difference in prevalence of reduced eGFR and elevated
albuminuria across racial groups was attenuated after age
standardization, particularly for reduced eGFR (Supplemen-
tary Figure S1C and D online). In the high-risk cohorts, the
crude prevalence of decreased eGFR and high albuminuria
were 11.6 and 24.0% in Asians, 18.7 and 20.6% in Whites,
and 10.4 and 13.5% in Blacks, respectively (Supplementary
Figure S2 online).
Incidence rates of mortality and ESRD by race
We observed 38,696 all-cause deaths and 9065 cardiovascular
disease (CVD) deaths in Asians (mean follow-up of 9.2
years), 20,079 and 7325 cases in Whites (mean follow-up of
8.4 years), and 2485 and 436 cases in Blacks (mean follow-up
of 6.6 years; Supplementary Table S1 online). Crude rates for
all-cause and CVD mortality in the general population
cohorts were 5.9 and 1.4 per 1000 person-years in Asians,
24.1 and 10.4 in Whites, and 18.7 and 5.5 in Blacks,
respectively (Supplementary Figure S3 online). After age
standardization, mortality rates were higher in Blacks
compared with that in Whites, whereas the lower rates in
Asians persisted. The variation in mortality rates was as great
among studies within races as among races within studies.
Among the studies with data on ESRD, crude incidence rates
of ESRD per 1000 person-years were 0.3 in Asians, 0.8 in
Whites, and 2.8 in Blacks.
Independent relationships of eGFR and albuminuria with
clinical risk by race
Figure 1 shows hazard ratios (HRs) for all-cause mortality,
CVD mortality, and ESRD in the general population cohorts
by race for eGFR from 15 to 120ml/min per 1.73m2 compared
with the reference point at eGFR 95ml/min per 1.73m2. The
patterns for each outcome were qualitatively similar among
three races across most of the range of eGFRs, with higher risk
at lower eGFR. For all-cause and CVD mortality, although
there was variation across races in the eGFR thresholds below
which the HRs were significantly greater than the reference
point, partially owing to difference in the precision of
estimates across races, the HR reached significance at eGFR
between 60 and 75ml/min per 1.73m2 in most analyses and
did not differ significantly for a given eGFR among races,
except for small ranges noted at the bottom of Figure 1. For
ESRD, the threshold eGFR varied from 65 to 83ml/min per
1.73m2 for all three races, although the pattern was least
steep in blacks for eGFR o30ml/min per 1.73m2.
Figure 2 shows HRs for all three outcomes by races
according to albuminuria categories (ACRo10, 10–29,
30–299, and X300mg/g or urine dipstick levels negative,
trace, 1þ and X2þ , respectively; Supplementary Figure S4
online shows the association for ACR as a continuous
variable). Again, the patterns for each outcome were similar
among races, with higher HRs for higher albuminuria. The
only significant difference was higher CVD mortality in Blacks
with ACR 30–299mg/g. In all races, the threshold category
above which the HRs for mortality outcomes was significantly
greater than the reference category was ACR X10mg/g or
dipstickXtrace. Although data were limited, the independent
associations of low eGFR and high albuminuria with three
outcomes were largely similar across three races in both high-
risk and CKD cohorts (Supplementary Figures S5–S8 online).
Combined relationships of eGFR and albuminuria with
clinical risk by race
Figure 3 shows the adjusted HRs for all-cause mortality, CVD
mortality, and ESRD in the general population cohorts by
eGFR and albuminuria categories compared with the reference
categories of eGFR 90–104ml/min per 1.73m2 and ACR
o10mg/g or dipstick negative. Consistent with the results in
Figures 1 and 2, all-cause mortality risks for eGFR categories
and albuminuria categories (marginal rows and columns in
Figure 3) were similar for Asians, Whites, and Blacks. For
example, in Asians, Whites, and Blacks, compared with
eGFR 90–104ml/min per 1.73m2, the HR (95% confidence
interval) for eGFR 45–59ml/min per 1.73m2 was 1.25
(1.20–1.31), 1.09 (0.97–1.22), and 1.33 (1.07–1.65) for all-
cause mortality, 1.59 (1.45–1.74), 1.40 (1.17–1.68), and 1.44
(0.72–2.86) for cardiovascular mortality, and 27.6 (11.1–68.7),
11.2 (6.01–20.9), and 4.05 (2.18–7.51) for ESRD, respectively.
The corresponding HRs for ACR 30–299mg/g or dipstick
1þ compared with ACRo10mg/g or dipstick negative were
1.61 (1.41–1.84), 1.68 (1.50–1.88), and 1.84 (1.65–2.06) for
all-cause mortality, 1.66 (1.37–2.01), 1.76 (1.49–2.09), and
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2.79 (2.15–3.62) for CVD mortality, and 7.39 (1.98–27.6), 4.04
(2.75–5.94), and 5.55 (3.36–9.18) for ESRD, respectively. The
HRs were quantitatively consistent across most of the studies
for three outcomes (Supplementary Figures S9–S11 online).
The pattern for categories based on eGFR and albuminur-
ia (cells in Figure 3) was also qualitatively similar among the
three races, showing a multiplicatively higher risk for lower
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Figure 2 | Association of albuminuria with all-cause mortality
(a), cardiovascular mortality (b), and end-stage renal disease (ESRD)
(c) across three racial groups in general population cohorts. The
whiskers represent 95% confidence intervals (95% CIs). The reference
category is urine albumin-to-creatinine ratio (ACR) o10mg/g or
dipstick negative. Dots represent statistically significant points.
Differences in hazard ratios (HRs) among racial groups were tested
using meta-regression with Whites as a reference. HRs were adjusted
for age, sex, smoking, systolic blood pressure, history of cardiovascular
disease, diabetes, serum total cholesterol concentration, body mass
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Figure 1 | Association of estimated glomerular filtration rate (eGFR)
with all-cause mortality (a), cardiovascular mortality (b), and
end-stage renal disease (ESRD) (c) across three racial groups in
general population cohorts. The shaded area or whiskers represent
95% confidence intervals (95% CIs). The reference (diamond) is eGFR
95ml/min per 1.73m2. Dots represent statistically significant points.
Difference in hazard ratios (HRs) among racial groups were tested
using meta-regression with Whites as a reference, and stars along the
bottom of each panel indicate a significant interaction at Po0.05.
HRs were adjusted for age, sex, smoking, systolic blood pressure,
history of cardiovascular disease, diabetes, serum total cholesterol
concentration, body mass index, and albuminuria.
822 Kidney International (2014) 86, 819–827
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Of note, the category of eGFR 45–59 with lowest albuminuria
was associated with a point estimate for the HR 41.0 com-
pared with the reference groups for all three outcomes for all
three races (statistically significant in 7 of 9 comparisons).
The category of elevated albuminuria (ACR 30–299mg/g or
urine dipstick 1þ ) with eGFR 90–104 was associated with a
point estimate for the HR41.0 compared with the reference
groups for all 9 comparisons (statistically significant in 8).
Similar results were observed for CVD mortality and ESRD.
Largely similar results were also observed across three races in
both high-risk and CKD cohorts (Supplementary Figures S12
and S13 online).
DISCUSSION
Low eGFR and high albuminuria were both independently
associated with an increased risk of mortality and ESRD. In
this unique and large meta-analysis, we observed qualitatively
similar adjusted HR for all-cause and cardiovascular
mortality and ESRD according to eGFR or albuminuria
across three major races, Asians, Whites, and Blacks, in
general population cohorts, despite differences in demo-
graphic and clinical characteristics (Table 1) and absolute risk
(Supplementary Figure S3 online) among racial groups and
cohorts. The consistency in eGFR and albuminuria risk
relationships across races has important implications for
clinical practice, research, and public health.
The best known racial disparities in kidney disease are the
widely different ESRD rates among countries reported by
the USRDS.16 Our results describing the highest ESRD rates
in Blacks are consistent with other studies.17–20 It is more
difficult to study racial differences in earlier stages of CKD.
There have not been large studies of multiracial populations
that have simultaneously assessed eGFR and albuminuria
regarding their associations with mortality and ESRD. In
addition, methods to estimate GFR and ascertain albumi-
nuria have varied, and many studies reported only eGFR or
albuminuria. Although our study has a wide variation in
demographic and clinical characteristics among cohorts, the
availability of both eGFR and albuminuria measurements
permits a more robust analysis.
Prior reports from the CKD-PC (Chronic Kidney Disease
Prognosis Consortium), using comparable methods across
cohorts, showed similar impact of eGFR and albuminuria
categories on relative risks of all-cause and cardiovascular
Figure 3 | Hazard ratios (HRs) of clinical outcomes according to estimated glomerular filtration rate (eGFR) and albuminuria categories
across three racial groups in general population cohorts. Each number represents a pooled HRs from meta-analysis adjusted for
covariates and compared with the reference cell (REF) within each race. Bold numbers indicate statistical significance at Po0.05. Color shading
indicates the strength of association (approximately one-quarter of all cells across racial groups are shaded in each color; green: low; yellow:
mild; orange: moderate; red: high). Difference in HRs among racial groups were tested using meta-regression with Whites as a reference;
*significant interaction at Po0.05.
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mortality and ESRD across subgroups defined by demo-
graphic and clinical characteristics (age,21 sex,22 hyper-
tension,23 and diabetes24). The current analysis expands
our prior observations to race groups and establishes a
consistency of the relationship of eGFR and albuminuria with
important outcomes irrespective of race. Given the increasing
interest in variability of incidence rates of ESRD across
countries and races, and the major resource implica-
tions associated with high ESRD rates, it will be important
to pursue the causes for the differences in distribution
of cardiovascular risk factors, eGFR, and albuminuria,
which we observed among the racial groups. Specifically, it
will be important to determine the extent to which social,
environmental, and genetic differences result in variation
in disease expression and outcomes (such as the higher
prevalence of IgA nephropathy in Asia and the contri-
bution of economic aspects to variation in dialysis care).25,26
A better understanding of the similarities and differences
across races should direct research to identify modifiable
factors.
The GFR thresholds for the definition and staging of CKD
were first proposed in 2002, using data derived predomi-
nantly from a general US population.1 In the past decade,
these eGFR thresholds have been incorporated into clinical
guidelines in other countries.3,27,28 The recognition of
albuminuria as an independent risk factor for adverse
outcomes has now led to the incorporation of albuminuria
categories into CKD staging, and this analysis has utilized the
new recommendations for categories of albuminuria and
eGFR.29 The robust relationship of eGFR and albuminuria
with outcomes irrespective of race gives additional credence
to their use in clinical arenas and beyond. Given the com-
plexity of using race-specific thresholds of kidney measures in
clinical practice, there would need to be strong evidence for
justification to support their adoption.
Standardization of methods for ascertainment of GFR
and albuminuria remains a challenge. Specification of race
improves the accuracy of creatinine-based GFR-estimating
equations by adjusting for differences in creatinine genera-
tion due to variation in muscle mass and diet. Current
guidelines recommend the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) creatinine equation for use in
North America, Europe, and Australia, which estimates GFR
B16% higher for Blacks compared with other races at a
given age, gender, and level of serum creatinine.30 In our
study, the CKD-EPI creatinine equation demonstrates similar
eGFR-risk association in Asians, Whites, and Blacks, providing
further support for its usefulness across racial groups and
encouraging more widespread reporting of eGFR around the
world. Other equations have been developed in Japanese,
Taiwanese, and Chinese, but their generalizability has not
been evaluated in large studies.31–34 In our consortium,
the selection of ACR versus dipstick for assessment of
albuminuria varies across regions/cohorts and is largely based
on study objectives and resources (with ACR being used most
commonly in North America, Europe, and Australia, and
dipsticks being most commonly used in Asia). Therefore, we
could not assess the influence of urinary creatinine per se,
which may vary substantially across races, on the association
between ACR and clinical risk.35 Nevertheless, this study
confirms the usefulness of both methods in relating albumi-
nuria with outcomes, thus supporting the use of either
method in clinical practice.
Strengths of our study include an international con-
sortium with a wide range of cohorts in various settings,
comprehensive data on eGFR and albuminuria, a large study
population, and the assessment of both mortality and ESRD.
The cohorts were not selected for previous publication
regarding the study question, thereby minimizing the
possibility of publication bias. The analysis was centrally
coordinated, and adjustment for important variables was
uniformly carried out in all cohorts. Our continuous analysis
using splines allowed inspection of the pattern of association
across the entire range of eGFR, irrespective of the reference
point used. The categorical analysis allowed combining
across cohorts that assessed albuminuria using ACR and
dipstick, and provided clinically useful information.
There are several limitations in our study. Measurements
of creatinine and urine albumin were not standardized in all
studies, and we did not have data on measured GFR, cystatin
C, or 24-h albumin excretion rate to confirm eGFR, urine
ACR, or dipstick.36 Only a few Asian cohorts had ACR
measurements, and none of them ascertained ESRD as an
outcome. Most of the Blacks in our study were from cohorts
in the United States and not from the Blacks in Africa. Most
Asians were in East-Asian cohorts, and we could not compare
East and South Asians. Few cohorts included multiple racial
groups. Further analyses will be required for Hispanics and
other racial/ethnic groups not represented in this study. We
cannot rule out the possibility of residual confounding due to
unevaluated variables in this study, such as lifestyle (e.g., diet
or physical activity) or socioeconomic status including access
to health care.
Despite wide variability in clinical characteristics among
cohorts and lower risk profile in Asian cohorts, there were no
substantial differences among Asians, Whites, and Blacks in
the independent and joint associations of reduced eGFR,
based on the CKD-EPI creatinine equation, and albuminuria,
based on ACR or dipstick, with all-cause and CVD mortality
and ESRD. These results support the use of existing eGFR
equations for risk categorization and thresholds of eGFR and




Details of the CKD-PC were described previously.8–12 To be included
in the consortium, a study had to have at least 1000 participants
(not applied to studies predominantly enrolling CKD patients (CKD
cohorts)9), information at baseline on eGFR and albuminuria, and a
minimum of 50 events for any of the outcomes of interest. This
analysis consists of data from 45 cohorts (25 general population
824 Kidney International (2014) 86, 819–827
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cohorts, 7 high-risk cohorts with high-risk participants selected for
cardiovascular or kidney disease risk factors, and 13 CKD cohorts;
Table 1, Supplementary Table S2 online, and Supplementary
Appendix 1 online). This study is based on secondary data analysis
of pre-existing, de-identified/de-linked data set, and was approved
by the Institutional Review Board at the Johns Hopkins Bloomberg
School of Public Health.
Study variables
GFR was estimated using the CKD-EPI creatinine equation:
141(minimum of standardized serum creatinine (mg/dl)/k or
1)a(maximum of standardized serum creatinine (mg/dl)/k
or 1) 1.2090.993age(1.018 if female)(1.159 if Black), where k
is 0.7 if female and 0.9 if male, and a is  0.329 if female
and  0.411 if male.37,38 For studies in which creatinine measure-
ment was not standardized to isotope dilution mass spectrometry,
we reduced the creatinine levels by 5%, the calibration factor used to
adjust nonstandardized Modification of Diet in Renal Disease Study
samples to isotope dilution mass spectrometry.39 Although urine
ACR is the preferred measure of albuminuria in the clinical
settings,1,3 the semiquantitative measurement using urine dipstick in
mass screening the healthy population has also been reported to be
highly valuable.40 A few studies that reported urine albumin
excretion or urine protein-to-creatinine ratio were also included.1
Race/ethnicity was categorized as Whites, Asian, Blacks, Hispanic,
and others. Owing to sparse data, we could not reliably investigate
Hispanics and other racial/ethnic groups (Supplementary Table S2
online), and thus their results were not shown. Diabetes mellitus was
defined as fasting glucose X7.0mmol/l, nonfasting glucose X11.1
mmol/l, hemoglobin A1cX6.5%, use of glucose-lowering drugs, or
self-reported diabetes. Hypertension was defined as systolic blood
pressureX140mmHg or diastolic blood pressureX90mmHg, use
of antihypertensive medication, or self-reported hypertension.
Hypercholesterolemia was defined as total cholesterol X5.0mmol/l
in people with prior CVD and asX6.0mmol/l otherwise, or the use
of lipid-lowering drugs. CVD history was defined as a history of
myocardial infarction, coronary revascularization, heart failure, or
stroke. Body mass index was calculated as weight (kg) divided by
square height (m). Smoking was dichotomized as current versus
former/nonsmokers. All of these study variables were assessed at
baseline in every cohort.
Outcomes
The three outcomes of interest were all-cause mortality, cardiovas-
cular mortality, and ESRD. Cardiovascular mortality was defined as
death due to myocardial infarction, heart failure, sudden cardiac
death, or stroke. ESRD was defined as start of renal replacement
therapy or death due to kidney disease. However, death due to acute
kidney injury was not included.41
Statistical analyses
Analyses were restricted to subjects aged 18 years or older. Any
subject with missing values for eGFR, albuminuria, and race/ethnicity
was excluded. Missing values for all other covariates were imputed
by the cohort mean. Age adjustment for distribution of kidney
measures and incidence rate of three outcomes was performed by
direct standardization using US NHANES III as the reference
population, the only cohort in the consortium representing national
data by design. The analysis overview and analytic notes for indivi-
dual studies are described in Supplementary Appendix 2 online.
We subsequently conducted a series of analyses stratified by
racial/ethnic groups. We used a two-stage approach in which stati-
stics were first obtained in each study and then were meta-analyzed
across studies by a random-effects model. General population, high-
risk, and CKD cohorts were meta-analyzed separately. Heterogeneity
was quantified using the w2-test for heterogeneity and the I2 statistic.
All analyses were conducted using the Stata/MP 11.2 software
(www.stata.com), and a P-value o0.05 was considered statistically
significant.
Cox proportional hazards models were used to estimate the
HRs of clinical outcomes associated with eGFR and albuminuria,
adjusted for age, sex, history of CVD, smoking, systolic blood
pressure (continuous), diabetes, serum total cholesterol concentra-
tion (continuous), body mass index (continuous), and either eGFR
or albuminuria as appropriate. Death was censored for ESRD
analysis. As few studies have multiple racial/ethnic groups, incorpo-
rating interaction terms between kidney measures and race in
models was not practical. Therefore, meta-regression analysis with a
random-effects model was used to formally compare HRs according
to eGFR and albuminuria across racial/ethnic groups.42 We modeled
eGFR and ACR using linear splines with knots at 30, 45, 60, 75, 90,
and 105ml/min per 1.73m2 (105 is not implemented for CKD
cohorts) and 10, 30, and 300mg/g (30, 300, and 1000mg/g for CKD
cohorts; to convert to mg/mmol multiply by 0.113), respectively. An
eGFR of 95ml/min per 1.73m2 (50 for CKD cohorts) and an ACR of
5mg/g (100 for CKD cohorts) were treated as reference points.8,9
We also compared the risk in categories of eGFR (o15, 15–29,
30–44, 45–59, 60–74, 75–89, 90–104, and X105ml/min per 1.73m2)
and albuminuria (ACR: o10, 10–29, 30–299, and X300mg/g;
protein-to-creatinine ratio: o15, 15–49, 50–499, and X500mg/g;
dipstick: negative ( ), trace (±), þ ,Xþ þ ), and their combina-
tion. For CKD cohorts, the following categories were used for eGFR
(o15, 15–29, 30–44, 45–74, 75–89, and X90ml/min per 1.73m2)
and albuminuria (ACR: o30, 30–299, 300–999, and X1000mg/g;
protein-to-creatinine ratio:o50, 50–499, 500–1499, andX1500mg/g;
dipstick: negative/trace, þ , þ þ , Xþ þ þ ). The category with
eGFR 90–104ml/min per 1.73m2 (45–74 for CKD cohorts) and the
lowest albuminuria was used as the reference group.8,9 Given that few
Asian cohorts had ACR data, results for albuminuria were primarily
shown for categories.
DISCLOSURE
All the authors declared no competing interests. All authors had full
access to the analysis reports and tables and take responsibility for
the integrity of the data and the accuracy of the data analysis. All
authors have completed the Unified Competing Interest form at
www.icmje.org/coi_disclosure.pdf (available on request from the
corresponding author).
ACKNOWLEDGMENTS
CKD-PC investigators/collaborators (Supplementary Appendix 1 lists
the study acronyms):
AASK: Jackson T Wright, Jr, Lawrence Appel, Tom Greene, Brad C
Astor; ADVANCE: John Chalmers, Stephen MacMahon, Mark
Woodward, Hisatomi Arima; Aichi: Hiroshi Yatsuya, Kentaro
Yamashita, Hideaki Toyoshima, Koji Tamakoshi; ARIC: Josef Coresh,
Brad C Astor, Kunihiro Matsushita, Yingying Sang; AusDiab: Robert C
Atkins, Kevan R Polkinghorne, Steven Chadban; Beaver Dam CKD:
Anoop Shankar, Ronald Klein, Barbara EK Klein, Kristine E Lee; Beijing
Cohort: Haiyan Wang, Fang Wang, Luxia Zhang, Li Zuo, Lisheng Liu;
British Columbia CKD: Adeera Levin, Ognjenka Djurdjev; CARE:
Marcello Tonelli, Frank Sacks, Gary Curhan; CHS: Michael Shlipak,
Kidney International (2014) 86, 819–827 825
CP Wen et al.: CKD and clinical risk across races c l in i ca l inves t iga t ion
Carmen Peralta, Ronit Katz, Linda Fried; CIRCS: Hiroyasu Iso, Akihiko
Kitamura, Tetsuya Ohira, Kazumasa Yamagishi; COBRA: Tazeen H
Jafar, Muhammad Islam, Juanita Hatcher, Neil Poulter, Nish
Chaturvedi; CRIB: Martin J Landray, Jonathan Emberson, Jonathan
Townend, David C Wheeler; ESTHER: Dietrich Rothenbacher,
Hermann Brenner, Heiko Mu¨ller, Ben Scho¨ttker; Framingham: Caroline
S Fox, Shih-Jen Hwang, James B Meigs; Geisinger: Robert M Perkins;
GLOMMS-1 Study: Nick Fluck, Laura Clark, Gordon J Prescott,
Angharad Marks, Corri Black; Gubbio: Massimo Cirillo; HUNT: Stein
Hallan, Knut Aasard, Cecilia M Øien, Marie Radtke; IPHS: Fujiko Irie,
Hiroyasu Iso, Toshimi Sairenchi, Kazumasa Yamagishi; Kaiser
Permanente NW: David H Smith, Jessica Weiss, Eric S Johnson, Micah
L Thorp; KEEP: Allan J Collins, Joseph A Vassalotti, Suying Li, Shu-
Cheng Chen; KP Hawaii: Brian J Lee; MASTERPLAN: Jack F. Wetzels,
Peter J Blankestijn, Arjan D van Zuilen; MDRD: Mark Sarnak, Andrew S
Levey, Lesley Inker, Vandana Menon; MESA: Michael Shlipak, Mark
Sarnak, Carmen Peralta, Ronit Katz, Linda F Fried, Holly Kramer, Ian de
Boer; MMKD: Florian Kronenberg, Barbara Kollerits, Eberhard Ritz;
MRC Older People: Paul Roderick, Dorothea Nitsch, Astrid Fletcher,
Christopher Bulpitt; MRFIT: Areef Ishani, James Neaton; NephroTest:
Marc Froissart, Benedicte Stengel, Marie Metzger, Jean-Philippe
Haymann, Pascal Houillier, Martin Flamant; NHANES III: Brad C Astor,
Josef Coresh, Kunihiro Matsushita; Ohasama: Takayoshi Ohkubo,
Hirohito Metoki, Masaaki Nakayama, Masahiro Kikuya, Yutaka Imai;
Okinawa 83/93: Kunitoshi Iseki; Pima Indian: Robert G Nelson, William
C Knowler; PREVEND: Ron T Gansevoort, Paul E de Jong, Bakhtawar
Khan Mahmoodi, Stephan JL Bakker; Rancho Bernardo: Simerjot Kaur
Jassal, Elizabeth Barrett-Connor, Jaclyn Bergstrom; RENAAL: Hiddo J
Lambers Heerspink, Barry Brenner, Dick de Zeeuw; Renal REGARDS:
David G Warnock, Paul Muntner, Suzanne Judd, William McClellan;
Severance: Sun Ha Jee, Heejin Kimm, Jaeseong Jo, Yejin Mok, Eunmi
Choi; STENO: Peter Rossing, Hans-Henrik Parving; Sunnybrook:
Navdeep Tangri, David Naimark; Taiwan GP: Chi Pang Wen, Sung-
Feng Wen, Chwen-Keng Tsao, Min-Kuang Tsai, Shiuan Be Wu; ULSAM:
Johan A¨rnlo¨v, Lars Lannfelt, Anders Larsson; ZODIAC: Henk J Bilo,
Hanneke Joosten, Nanne Kleefstra, Klaas H Groenier, Iefke Drion; CKD-
PC Steering Committee: Brad C Astor, Josef Coresh (Chair), Ron T
Gansevoort, Brenda R Hemmelgarn, Paul E de Jong, Andrew S Levey,
Adeera Levin, Kunihiro Matsushita, Chi Pang Wen, Mark Woodward;
CKD-PC Data Coordinating Center: Shoshana H Ballew (Coordinator),
Josef Coresh (Principal investigator), Morgan Grams, Bakhtawar Khan
Mahmoodi, Kunihiro Matsushita (Director), Yingying Sang (Lead
programmer), Mark Woodward (Senior statistician); administrative
support: Laura Camarata, Xuan Hui, Jennifer Seltzer, Heather
Winegrad.
The CKD-PC Data Coordinating Center is funded in part by a
program grant from the US National Kidney Foundation (NKF funding
sources include Abbott) and an investigator-initiated research grant
from Amgen. A variety of sources have supported enrollment and
data collection, including laboratory measurements and follow-up in
the collaborating cohorts of the CKD-PC. These funding sources
include government agencies such as national institutes of health
and medical research councils, as well as foundations and industry
sponsors listed in Supplementary Appendix 3 online. The funders had
no role in the design, analysis, interpretation of this study, and did
not contribute to the writing of this report and the decision to submit
the article for publication. The sponsors had no role in the design
and conduct of the study; in the collection, analysis, and
interpretation of the data, or in the preparation, review, or approval
of the manuscript. A variation of this analysis was presented at the
American Society of Nephrology Kidney Week 2012 (San Diego, CA,
3 November 2012).
AUTHOR CONTRIBUTIONS
Conception and design: CPW, KM, JC, BCA, RTG, ASL, and AL, CKD
Prognosis Consortium. Analysis and interpretation of the data, critical
revision of the article for important intellectual content, and final
approval of the article: CPW, KM, JC, KI, MI, RK, WMcC, CAP, HW, DdZ,
BCA, RTG, ASL, and AL, CKD Prognosis Consortium. Statistical
expertise, obtaining of funding, administrative, technical, or logistic
support, and collection and assembly of data: KM and JC, CKD
Prognosis Consortium.
SUPPLEMENTARY MATERIAL
Appendix 1. Acronyms or abbreviations for studies included in the
current report and their key references linked to the Web references.
Appendix 2. Data analysis overview and analytic notes for some of
individual studies.
Appendix 3. Acknowledgments and funding for collaborating
cohorts.
Table S1. Number of events per study for Asians, Whites, and Blacks.
Table S2. Characteristics of individual studies by ethnicity for
Hispanics and others.
Figure S1. Crude and age-standardized distribution of eGFR and
albuminuria across races in the general population cohorts. Panels A
(eGFR) and B (albuminuria) show crude distribution, whereas panels C
(eGFR) and D (albuminuria) are adjusted for age by direct
standardization using US NHANES III as a reference population.
Green, black, and red bars denote the proportions of Asian, White,
and Black populations, respectively.
Figure S2. Distribution of eGFR (A and C) and albuminuria (B and D)
across races in high-risk (A and B) and CKD (C and D) cohorts. Panels
A (eGFR) and B (albuminuria) show high-risk cohorts, whereas panels
C (eGFR) and D (albuminuria) show CKD cohorts. Green, black, and
red bars denote the proportions of Asian, White, and Black
populations, respectively.
Figure S3. Absolute risk overall of all-cause mortality (A and B),
cardiovascular mortality (C and D), and ESRD (E and F) in general
population cohorts.
Figure S4. Association of ACR by ethnicity with all-cause mortality (A)
and cardiovascular mortality (B) in general population cohorts.
Figure S5. Association of eGFR by ethnicity with all-cause mortality
(A) and cardiovascular mortality (B) in high-risk cohorts.
Figure S6. Association of eGFR by ethnicity with all-cause mortality
(A), cardiovascular mortality (B), and ESRD (C) in CKD cohorts.
Figure S7. Association of ACR by ethnicity with all-cause mortality (A)
and cardiovascular mortality (B) in high-risk cohorts.
Figure S8. Association of ACR/protein-to-creatinine ratio (PCR) by
ethnicity with all-cause mortality (A), cardiovascular mortality (B), and
ESRD (C) in chronic kidney disease cohorts.
Figure S9. Forest plot across general population studies by grouping
of Asians, Whites, and Blacks at eGFR 45–59 category and albuminuria
30–299 category for all-cause mortality.
Figure S10. Forest plot across general population studies by
grouping of Asians, Whites, and Blacks at eGFR 45–59 category and
albuminuria 30–299 category for cardiovascular mortality.
Figure S11. Forest plot across general population studies by
grouping of Asians, Whites, and Blacks at eGFR 45–59 category and
albuminuria 30–299 category for end-stage renal disease.
Figure S12. Relative risk of all-cause and cardiovascular mortality
according to eGFR and ACR/dipstick categories in Whites, Asians, and
Blacks in high-risk cohorts.
Figure S13. Relative risk of all-cause and cardiovascular mortality
according to eGFR and ACR/dipstick categories in Whites, Asians, and
Blacks in chronic kidney disease cohorts.
Support Materials References.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic
kidney disease: Evaluation, classification, and stratification—Foreword.
Am J Kidney Dis 2002; 39: S14–S266.
826 Kidney International (2014) 86, 819–827
c l in i ca l inves t iga t ion CP Wen et al.: CKD and clinical risk across races
2. Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global
public health problem: approaches and initiatives - A position statement
from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72:
247–259.
3. Crowe E, Halpin D, Stevens P. Guidelines: early identification and
management of chronic kidney disease: summary of NICE guidance. BMJ
2008; 337: 812–815.
4. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in
Australian adults: The AusDiab Kidney Study. J Am Soc Nephrol 2003; 14:
S131–S138.
5. Hallan SI, Coresh J, Astor BC et al. International comparison of the
relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc
Nephrol 2006; 17: 2275–2284.
6. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease
in the United States. JAMA 2007; 298: 2038–2047.
7. Wen CP, Cheng TY, Tsai MK et al. All-cause mortality attributable to
chronic kidney disease: a prospective cohort study based on 462 293
adults in Taiwan. Lancet 2008; 371: 2173–2182.
8. Matsushita K, van der Velde M, Astor BC et al. Association of estimated
glomerular filtration rate and albuminuria with all-cause and
cardiovascular mortality in general population cohorts: a collaborative
meta-analysis. Lancet 2010; 375: 2073–2081.
9. Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular
filtration rate and higher albuminuria are associated with mortality and
end-stage renal disease. A collaborative meta-analysis of kidney disease
population cohorts. Kidney Int 2011; 79: 1331–1340.
10. Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated
GFR and higher albuminuria are associated with adverse kidney
outcomes in both general and high-risk populations. A collaborative
meta-analysis of general and high-risk population cohorts. Kidney Int
2011; 80: 93–104.
11. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and
prognosis of chronic kidney disease: a KDIGO Controversies Conference
report. Kidney Int 2011; 80: 17–28.
12. van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular
filtration rate and higher albuminuria are associated with all-cause and
cardiovascular mortality. A collaborative meta-analysis of high-risk
population cohorts. Kidney Int 2011; 79: 1341–1352.
13. Tonelli M, Muntner P, Lloyd A et al. Using proteinuria and estimated
glomerular filtration rate to classify risk in patients with chronic kidney
disease: a cohort study. Ann Intern Med 2011; 154: 12–21.
14. de Zeeuw D, Ramjit D, Zhang Z et al. Renal risk and renoprotection
among ethnic groups with type 2 diabetic nephropathy: a post hoc
analysis of RENAAL. Kidney Int 2006; 69: 1675–1682.
15. Winearls CG, Glassock RJ. Dissecting and refining the staging of chronic
kidney disease. Kidney Int 2009; 75: 1009–1014.
16. US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic
Kidney Disease and End-Stage Renal Disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases: Bethesda, MD, 2012.
17. Conley J, Tonelli M, Quan H et al. Association between GFR, proteinuria,
and adverse outcomes among White, Chinese, and South Asian
individuals in Canada. Am J Kidney Dis 2012; 59: 390–399.
18. Jolly SE, Burrows NR, Chen SC et al. Racial and ethnic differences in
mortality among individuals with chronic kidney disease: results from the
Kidney Early Evaluation Program (KEEP). Clin J Am Soc Nephrol 2011; 6:
1858–1865.
19. Barbour SJ, Er L, Djurdjev O et al. Differences in progression of CKD and
mortality amongst Caucasian, Oriental Asian and South Asian CKD
patients. Nephrol Dial Transplant 2010; 25: 3663–3672.
20. Mehrotra R, Kermah D, Fried L et al. Racial differences in mortality among
those with CKD. J Am Soc Nephrol 2008; 19: 1403–1410.
21. Hallan SI, Matsushita K, Sang Y et al. Age and association of kidney
measures with mortality and end-stage renal disease. JAMA 2012; 308:
2349–2360.
22. Nitsch D, Grams ME, Sang Y et al. Associations of estimated glomerular
filtration rate and albuminuria with mortality and renal failure by sex: a
meta-analysis. BMJ 2013; 346: f324.
23. Mahmoodi BK, Matsushita K, Woodward M et al. Associations of kidney
disease measures with mortality and end-stage renal disease in
individuals with and without hypertension: a meta-analysis. Lancet 2012;
380: 1649–1661.
24. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease
measures with mortality and end-stage renal disease in individuals with
and without diabetes: a meta-analysis. Lancet 2012; 380: 1662–1673.
25. Yamagata K, Iseki K, Nitta K et al. Chronic kidney disease perspectives in
Japan and the importance of urinalysis screening. Clin Exp Nephrol 2008;
12: 1–8.
26. Devereaux PJ, Schunemann HJ, Ravindran N et al. Comparison of
mortality between private for-profit and private not-for-profit
hemodialysis centers: a systematic review and meta-analysis. JAMA 2002;
288: 2449–2457.
27. Japanese Society of Nephrology. Evidence-based practice guideline for
the treatment of CKD. Clin Exp Nephrol 2009; 13: 537–566.
28. Levin A, Hemmelgarn B, Culleton B et al. Guidelines for the management
of chronic kidney disease. Can Med Assoc J 2008; 179: 1154–1162.
29. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.
KDIGO 2012 clinical practice guideline for the evaluation and
management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150.
30. Earley A, Miskulin D, Lamb EJ et al. Estimating equations for glomerular
filtration rate in the era of creatinine standardization: a systematic review.
Ann Intern Med 2012; 156: 785–795.
31. Horio M, Imai E, Yasuda Y et al. Modification of the CKD Epidemiology
Collaboration (CKD-EPI) equation for Japanese: accuracy and use for
population estimates. Am J Kidney Dis 2010; 56: 32–38.
32. Teo BW, Xu H, Wang DH et al. GFR estimating equations in a multiethnic
Asian population. Am J Kidney Dis 2011; 58: 56–63.
33. Du X, Hu B, Jiang L et al. Implication of CKD-EPI equation to estimate
glomerular filtration rate in Chinese patients with chronic kidney disease.
Ren Fail 2011; 33: 859–865.
34. Stevens LA, Claybon MA, Schmid CH et al. Evaluation of the chronic kidney
disease epidemiology collaboration equation for estimating the glomerular
filtration rate in multiple ethnicities. Kidney Int 2011; 79: 555–562.
35. Carter CE, Gansevoort RT, Scheven L et al. Influence of urine creatinine on
the relationship between the albumin-to-creatinine ratio and
cardiovascular events. Clin J Am Soc Nephrol 2012; 7: 595–603.
36. Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration
rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20–29.
37. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate
glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
38. Matsushita K, Mahmoodi BK, Woodward M et al. Comparison of risk
prediction using the CKD-EPI equation and the MDRD study equation for
estimated glomerular filtration rate. JAMA 2012; 307: 1941–1951.
39. Levey AS, Coresh J, Greene T et al. Expressing the modification of diet in
renal disease study equation for estimating glomerular filtration rate with
standardized serum creatinine values. Clin Chem 2007; 53: 766–772.
40. Wen CP, Yang YC, Tsai MK et al. Urine dipstick to detect trace proteinuria:
an underused tool for an underappreciated risk marker. Am J Kidney Dis
2011; 58: 1–3.
41. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet 2012; 380:
756–766.
42. Thompson S, Kaptoge S, White I et al. Statistical methods for the time-to-
event analysis of individual participant data from multiple
epidemiological studies. Int J Epidemiol 2010; 39: 1345–1359.
Kidney International (2014) 86, 819–827 827
CP Wen et al.: CKD and clinical risk across races c l in i ca l inves t iga t ion
